Chronic stable angina risk stratification: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 1: Line 1:
{{SI}}
__NOTOC__
{{WikiDoc Cardiology Network Infobox}}
{{Chronic stable angina}}
{{CMG}}; {{CZ}}
{{CMG}}; '''Associate Editors-in-Chief:''' {{CZ}}; Smita Kohli, M.D.
 
'''Associate Editor-in-Chief:''' Smita Kohli, M.D.
 
{{EH}}
 
 
'''Click [[Chronic stable angina|''here'']] for the Chronic stable angina main page'''
 


==Overview==
==Overview==


The average mortality in patients with stable angina ranges from 1-3%. However, there is a wide variability in the prognosis and
The average mortality in patients with stable angina ranges from '''1-3%.'''However, there is a wide variability in the prognosis and
hence it is important to risk stratify every patient. Risk stratification is based on 4 types of patient characteristics.   
hence it is important to risk stratify every patient. Risk stratification is based on 4 types of patient characteristics.   
* Left ventricular function, which is the strongest predictor of long term survival
* Left ventricular function, which is the strongest predictor of long term survival
Line 33: Line 25:
Indications for assessing LV function are not only limited to patients with evidence of heart failure or valvular dysfunction but also includes patients with documented [[MI]] or [[ECG]] showing Q waves(suggestive of old MI). A resting or exercise LV ejection fraction of less than 35% is associated with significant higher mortality than a normal EF. [[Echocardiography]] is the best initial tool for obtaining an estimate of the LV function, both systolic and diastolic. In addition to this, it will also provide information about associated valvular dysfunction and pulmonary artery pressures. This information can in turn be used to select or modify the treatment regimen for the patient.
Indications for assessing LV function are not only limited to patients with evidence of heart failure or valvular dysfunction but also includes patients with documented [[MI]] or [[ECG]] showing Q waves(suggestive of old MI). A resting or exercise LV ejection fraction of less than 35% is associated with significant higher mortality than a normal EF. [[Echocardiography]] is the best initial tool for obtaining an estimate of the LV function, both systolic and diastolic. In addition to this, it will also provide information about associated valvular dysfunction and pulmonary artery pressures. This information can in turn be used to select or modify the treatment regimen for the patient.


==ACC / AHA Guidelines- Measurement of Rest LV Function by Echocardiography or Radionuclide Angiography (DO NOT EDIT)<ref name="Gibbons1"> Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP–ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). Circulation. 1999; 99: 2829–2848. PMID 10351980</ref>==
==ACC / AHA Guidelines- Measurement of rest LV function by echocardiography or radionuclide angiography (DO NOT EDIT)<ref name="Gibbons1"> Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP–ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). Circulation. 1999; 99: 2829–2848. PMID 10351980</ref>==
{{cquote|
{{cquote|
===Class I===
===Class I===
1. [[Echocardiography]] or [[radionuclide angiography]] (RNA) in patients with a history of prior [[MI]], pathological Q waves, or symptoms or signs suggestive of [[heart failure]] to assess [[LV function]]. ''(Level of Evidence: B)''
'''1.''' [[Echocardiography]] or [[radionuclide angiography]] (RNA) in patients with a history of prior [[MI]], pathological Q waves, or symptoms or signs suggestive of [[heart failure]] to assess [[LV function]]. ''(Level of Evidence: B)''


2. [[Echocardiography]] in patients with a [[systolic murmur]] suggesting [[mitral regurgitation]] to assess its severity and etiology. ''(Level of Evidence: C)''
'''2.'''[[Echocardiography]] in patients with a [[systolic murmur]] suggesting [[mitral regurgitation]] to assess its severity and etiology. ''(Level of Evidence: C)''


3. [[Echocardiography]] or RNA in patients with complex [[ventricular arrhythmia]]s to assess [[LV function]]. ''(Level of Evidence: B)''
'''3.'''[[Echocardiography]] or RNA in patients with complex [[ventricular arrhythmia]]s to assess [[LV function]]. ''(Level of Evidence: B)''


===Class III===
===Class III===
1. Routine periodic reassessment of stable patients for whom no new change in therapy is contemplated. ''(Level of Evidence: C)''
'''1.''' Routine periodic reassessment of stable patients for whom no new change in therapy is contemplated. ''(Level of Evidence: C)''


2. Patients with a normal [[ECG]], no history of [[MI]], and no symptoms or signs suggestive of [[heart failure]]. ''(Level of Evidence: B)''}}
'''2.''' Patients with a normal [[ECG]], no history of [[MI]], and no symptoms or signs suggestive of [[heart failure]]. ''(Level of Evidence: B)''}}




===Exercise testing for Risk Stratification and Prognosis===
==Exercise testing for Risk Stratification and Prognosis==


==ACC / AHA Guidelines- Risk Assessment and Prognosis in Patients With an Intermediate or High Probability of CAD (DO NOT EDIT)<ref name="Gibbons1"> Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP–ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). Circulation. 1999; 99: 2829–2848. PMID 10351980</ref>==
==ACC / AHA Guidelines- Risk Assessment and Prognosis in Patients With an Intermediate or High Probability of CAD (DO NOT EDIT)<ref name="Gibbons1"> Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP–ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). Circulation. 1999; 99: 2829–2848. PMID 10351980</ref>==
{{cquote|
{{cquote|
===Class I===
===Class I===
1. Patients undergoing initial evaluation. (Exceptions are listed below in classes IIb and III.) ''(Level of Evidence: B)''
'''1.''' Patients undergoing initial evaluation. (Exceptions are listed below in classes IIb and III.) ''(Level of Evidence: B)''


2. Patients after a significant change in cardiac symptoms. ''(Level of Evidence: C)''
'''2.''' Patients after a significant change in cardiac symptoms. ''(Level of Evidence: C)''


===Class IIb===
===Class IIb===
1. Patients with the following [[ECG]] abnormalities:
'''1.''' Patients with the following [[ECG]] abnormalities:
:a. Preexcitation ([[Wolff-Parkinson-White syndrome|Wolff-Parkinson-White]]) syndrome. ''(Level of Evidence: B)''
:a. Preexcitation ([[Wolff-Parkinson-White syndrome|Wolff-Parkinson-White]]) syndrome. ''(Level of Evidence: B)''
:b. Electronically paced ventricular rhythm. ''(Level of Evidence: B)''
:b. Electronically paced ventricular rhythm. ''(Level of Evidence: B)''
Line 64: Line 56:
:d. Complete [[left bundle-branch block]]. ''(Level of Evidence: B)''
:d. Complete [[left bundle-branch block]]. ''(Level of Evidence: B)''


2. Patients who have undergone [[cardiac catheterization]] to identify [[ischemia]] in the distribution of a coronary lesion of borderline severity. ''(Level of Evidence: C)''
'''2.''' Patients who have undergone [[cardiac catheterization]] to identify [[ischemia]] in the distribution of a coronary lesion of borderline severity. ''(Level of Evidence: C)''


3. [[Revascularization|Postrevascularization]] patients who have a significant change in anginal pattern suggesting [[ischemia]]. ''(Level of Evidence: C)''
'''3.'''[[Revascularization|Postrevascularization]] patients who have a significant change in anginal pattern suggesting [[ischemia]]. ''(Level of Evidence: C)''


===Class III===
===Class III===
1. Patients with severe [[comorbidity]] likely to limit life expectancy or prevent [[revascularization]]. ''(Level of Evidence: C)''}}
'''1.''' Patients with severe [[comorbidity]] likely to limit life expectancy or prevent [[revascularization]]. ''(Level of Evidence: C)''}}


==ACC / AHA Guidelines- Cardiac Stress Imaging for Risk Stratification of Patients With Chronic Stable Angina Who Are Able to Exercise (DO NOT EDIT)<ref name="Gibbons1"> Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP–ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). Circulation. 1999; 99: 2829–2848. PMID 10351980</ref>==
==ACC / AHA Guidelines- Cardiac Stress Imaging for Risk Stratification of Patients With Chronic Stable Angina Who Are Able to Exercise (DO NOT EDIT)<ref name="Gibbons1"> Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP–ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). Circulation. 1999; 99: 2829–2848. PMID 10351980</ref>==
{{cquote|
{{cquote|
===Class I===
===Class I===
1. Exercise myocardial perfusion imaging or exercise [[echocardiography]] to identify the extent, severity, and location of [[ischemia]] in patients who do not have [[left bundle-branch block]] or an electronically paced ventricular rhythm and have either an abnormal rest [[ECG]] or are using [[digoxin]]. ''(Level of Evidence: B)''
'''1.''' Exercise myocardial perfusion imaging or exercise [[echocardiography]] to identify the extent, severity, and location of [[ischemia]] in patients who do not have [[left bundle-branch block]] or an electronically paced ventricular rhythm and have either an abnormal rest [[ECG]] or are using [[digoxin]]. ''(Level of Evidence: B)''


2. [[Dipyridamole]] or [[adenosine]] myocardial perfusion imaging in patients with [[left bundle-branch block]] or electronically paced ventricular rhythm. ''(Level of Evidence: B)''
'''2.'''[[Dipyridamole]] or [[adenosine]] myocardial perfusion imaging in patients with [[left bundle-branch block]] or electronically paced ventricular rhythm. ''(Level of Evidence: B)''


3. Exercise myocardial perfusion imaging or exercise [[echocardiography]] to assess the functional significance of coronary lesions (if not already known) in planning [[PTCA]]. ''(Level of Evidence: B)''
'''3.''' Exercise myocardial perfusion imaging or exercise [[echocardiography]] to assess the functional significance of coronary lesions (if not already known) in planning [[PTCA]]. ''(Level of Evidence: B)''


===Class IIb===
===Class IIb===
1. Exercise or [[dobutamine]] [[echocardiography]] in patients with [[left bundle-branch block]]. ''(Level of Evidence: C)''
'''1.''' Exercise or [[dobutamine]] [[echocardiography]] in patients with [[left bundle-branch block]]. ''(Level of Evidence: C)''


2. Exercise, [[dipyridamole]], [[adenosine]] myocardial perfusion imaging, or exercise or [[dobutamine]] [[echocardiography]] as the initial test in patients who have a normal rest [[ECG]] and are not taking [[digoxin]]. ''(Level of Evidence: B)''
'''2.''' Exercise, [[dipyridamole]], [[adenosine]] myocardial perfusion imaging, or exercise or [[dobutamine]] [[echocardiography]] as the initial test in patients who have a normal rest [[ECG]] and are not taking [[digoxin]]. ''(Level of Evidence: B)''


===Class III===
===Class III===
1. Exercise myocardial perfusion imaging in patients with left [[bundle-branch block]]. ''(Level of Evidence: C)''
'''1.''' Exercise myocardial perfusion imaging in patients with left [[bundle-branch block]]. ''(Level of Evidence: C)''


2. Exercise, [[dipyridamole]], [[adenosine]] myocardial perfusion imaging, or exercise or [[dobutamine]] [[echocardiography]] in patients with severe [[comorbidity]] likely to limit life expectation or prevent [[revascularization]]. ''(Level of Evidence: C)''}}
'''2.''' Exercise, [[dipyridamole]], [[adenosine]] myocardial perfusion imaging, or exercise or [[dobutamine]] [[echocardiography]] in patients with severe [[comorbidity]] likely to limit life expectation or prevent [[revascularization]]. ''(Level of Evidence: C)''}}




Line 94: Line 86:
{{cquote|
{{cquote|
===Class I===
===Class I===
1. [[Dipyridamole]] or [[adenosine]] myocardial perfusion imaging or [[dobutamine]] [[echocardiography]] to identify the extent, severity, and location of [[ischemia]] in patients who do not have [[left bundle-branch block]] or electronically paced ventricular rhythm. ''(Level of Evidence: B)''
'''1.'''[[Dipyridamole]] or [[adenosine]] myocardial perfusion imaging or [[dobutamine]] [[echocardiography]] to identify the extent, severity, and location of [[ischemia]] in patients who do not have [[left bundle-branch block]] or electronically paced ventricular rhythm. ''(Level of Evidence: B)''


2. [[Dipyridamole]] or [[adenosine]] myocardial perfusion imaging in patients with [[left bundle-branch block]] or electronically paced ventricular rhythm. ''(Level of Evidence: B)''
'''2.'''[[Dipyridamole]] or [[adenosine]] myocardial perfusion imaging in patients with [[left bundle-branch block]] or electronically paced ventricular rhythm. ''(Level of Evidence: B)''


3. [[Dipyridamole]] or [[adenosine]] myocardial perfusion imaging or [[dobutamine]] [[echocardiography]] to assess the functional significance of coronary lesions (if not already known) in planning [[PTCA]]. ''(Level of Evidence: B)''
'''3.'''[[Dipyridamole]] or [[adenosine]] myocardial perfusion imaging or [[dobutamine]] [[echocardiography]] to assess the functional significance of coronary lesions (if not already known) in planning [[PTCA]]. ''(Level of Evidence: B)''


===Class IIb===
===Class IIb===
1. [[Dobutamine]] [[echocardiography]] in patients with [[left bundle-branch block]]. ''(Level of Evidence: C)''
'''1.'''[[Dobutamine]] [[echocardiography]] in patients with [[left bundle-branch block]]. ''(Level of Evidence: C)''


===Class III===
===Class III===
1. [[Dipyridamole]] or [[adenosine]] myocardial perfusion imaging or [[dobutamine]] [[echocardiography]] in patients with severe [[comorbidity]] likely to limit life expectation or prevent [[revascularization]]. ''(Level of Evidence: C)''}}
'''1.'''[[Dipyridamole]] or [[adenosine]] myocardial perfusion imaging or [[dobutamine]] [[echocardiography]] in patients with severe [[comorbidity]] likely to limit life expectation or prevent [[revascularization]]. ''(Level of Evidence: C)''}}


==ACC / AHA Guidelines- Coronary Angiography and Left Ventriculography (DO NOT EDIT)<ref name="Gibbons1"> Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP–ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). Circulation. 1999; 99: 2829–2848. PMID 10351980</ref>==
==ACC / AHA Guidelines- Coronary Angiography and Left Ventriculography (DO NOT EDIT)<ref name="Gibbons1"> Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP–ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). Circulation. 1999; 99: 2829–2848. PMID 10351980</ref>==
{{cquote|
{{cquote|
===Class I===
===Class I===
1. Patients with disabling (Canadian Cardiovascular Society (CCS) classes III and IV) chronic stable angina despite medical therapy. ''(Level of Evidence: B)''
'''1.''' Patients with disabling (Canadian Cardiovascular Society (CCS) classes III and IV) chronic stable angina despite medical therapy. ''(Level of Evidence: B)''


2. Patients with high-risk criteria on noninvasive testing regardless of anginal severity. ''(Level of Evidence: B)''
'''2.''' Patients with high-risk criteria on noninvasive testing regardless of anginal severity. ''(Level of Evidence: B)''


3. Patients with [[angina]] who have survived [[sudden cardiac death]] or serious [[ventricular arrhythmia]]. ''(Level of Evidence: B)''
'''3.''' Patients with [[angina]] who have survived [[sudden cardiac death]] or serious [[ventricular arrhythmia]]. ''(Level of Evidence: B)''


4. Patients with [[angina]] and symptoms and signs of [[congestive heart failure]]. ''(Level of Evidence: C)''
'''4.''' Patients with [[angina]] and symptoms and signs of [[congestive heart failure]]. ''(Level of Evidence: C)''


5. Patients with clinical characteristics that indicate a high likelihood of severe [[CAD]]. ''(Level of Evidence: C)''
'''5.''' Patients with clinical characteristics that indicate a high likelihood of severe [[CAD]]. ''(Level of Evidence: C)''


===Class IIa===
===Class IIa===
1. Patients with significant [[LV dysfunction]] (ejection fraction <45%), CCS class I or II angina, and demonstrable [[ischemia]] but less than high-risk criteria on noninvasive testing. ''(Level of Evidence: C)''
'''1.''' Patients with significant [[LV dysfunction]] (ejection fraction <45%), CCS class I or II angina, and demonstrable [[ischemia]] but less than high-risk criteria on noninvasive testing. ''(Level of Evidence: C)''


2. Patients with inadequate prognostic information after noninvasive testing. ''(Level of Evidence: C)''
'''2.''' Patients with inadequate prognostic information after noninvasive testing. ''(Level of Evidence: C)''


===Class IIb===
===Class IIb===
1. Patients with CCS class I or II [[angina]], preserved [[LV function]] (ejection fraction >45%), and less than high-risk criteria on noninvasive testing. ''(Level of Evidence: C)''
'''1.''' Patients with CCS class I or II [[angina]], preserved [[LV function]] (ejection fraction >45%), and less than high-risk criteria on noninvasive testing. ''(Level of Evidence: C)''


===Class III===
===Class III===
1. Patients with CCS class I or II [[angina]] who respond to medical therapy and have no evidence of [[ischemia]] on noninvasive testing. ''(Level of Evidence: C)''
'''1.''' Patients with CCS class I or II [[angina]] who respond to medical therapy and have no evidence of [[ischemia]] on noninvasive testing. ''(Level of Evidence: C)''


2. Patients who prefer to avoid [[revascularization]]. ''(Level of Evidence: C)''}}
'''2.''' Patients who prefer to avoid [[revascularization]]. ''(Level of Evidence: C)''}}


===Asymptomatic patients===
==Asymptomatic patients==


==ACC / AHA Guidelines- Noninvasive Testing for the Diagnosis of Obstructive CAD and Risk Stratification in Asymptomatic Patients (DO NOT EDIT)<ref name="Gibbons2">Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, Ferguson TB Jr, Fihn SD, Fraker TD Jr, Gardin JM, O'Rourke RA, Pasternak RC, Williams SV, Gibbons RJ, Alpert JS, Antman EM, Hiratzka LF, Fuster V, Faxon DP, Gregoratos G, Jacobs AK, Smith SC Jr; American College of Cardiology; American Heart Association Task Force on Practice Guidelines. Committee on the Management of Patients With Chronic Stable Angina. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation. 2003 Jan 7; 107 (1): 149-58. PMID 12515758 </ref>==
==ACC / AHA Guidelines- Noninvasive Testing for the Diagnosis of Obstructive CAD and Risk Stratification in Asymptomatic Patients (DO NOT EDIT)<ref name="Gibbons2">Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, Ferguson TB Jr, Fihn SD, Fraker TD Jr, Gardin JM, O'Rourke RA, Pasternak RC, Williams SV, Gibbons RJ, Alpert JS, Antman EM, Hiratzka LF, Fuster V, Faxon DP, Gregoratos G, Jacobs AK, Smith SC Jr; American College of Cardiology; American Heart Association Task Force on Practice Guidelines. Committee on the Management of Patients With Chronic Stable Angina. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation. 2003 Jan 7; 107 (1): 149-58. PMID 12515758 </ref>==
{{cquote|
{{cquote|
===Class IIb===
===Class IIb===
1. Exercise [[ECG]] testing without an imaging modality in asymptomatic patients with possible [[myocardial ischemia]] on [[ambulatory ECG]] ([[AECG]]) monitoring or with severe [[coronary calcification]] on [[EBCT]] in the absence of one of the following [[ECG]] abnormalities:
'''1.''' Exercise [[ECG]] testing without an imaging modality in asymptomatic patients with possible [[myocardial ischemia]] on [[ambulatory ECG]] ([[AECG]]) monitoring or with severe [[coronary calcification]] on [[EBCT]] in the absence of one of the following [[ECG]] abnormalities:
:a. Preexcitation ([[Wolff-Parkinson-White syndrome|Wolff-Parkinson-White]]) syndrome ''(Level of Evidence: C)''
:a. Preexcitation ([[Wolff-Parkinson-White syndrome|Wolff-Parkinson-White]]) syndrome ''(Level of Evidence: C)''
:b. Electronically paced ventricular rhythm ''(Level of Evidence: C)''
:b. Electronically paced ventricular rhythm ''(Level of Evidence: C)''
Line 143: Line 135:
:d. Complete [[left bundle-branch block]]. ''(Level of Evidence: C)''
:d. Complete [[left bundle-branch block]]. ''(Level of Evidence: C)''


2. Exercise perfusion imaging or exercise [[echocardiography]] in asymptomatic patients with possible [[myocardial ischemia]] on [[AECG]] monitoring or with severe [[coronary calcification]] on [[EBCT]] who are able to exercise and have one of the following baseline [[ECG]] abnormalities:
'''2.''' Exercise perfusion imaging or exercise [[echocardiography]] in asymptomatic patients with possible [[myocardial ischemia]] on [[AECG]] monitoring or with severe [[coronary calcification]] on [[EBCT]] who are able to exercise and have one of the following baseline [[ECG]] abnormalities:
:a. Preexcitation ([[Wolff-Parkinson-White syndrome|Wolff-Parkinson-White]]) syndrome ''(Level of Evidence: C)''
:a. Preexcitation ([[Wolff-Parkinson-White syndrome|Wolff-Parkinson-White]]) syndrome ''(Level of Evidence: C)''
:b. More than 1 mm of ST depression at rest. ''(Level of Evidence: C)''
:b. More than 1 mm of ST depression at rest. ''(Level of Evidence: C)''


3. [[Adenosine]] or [[dipyridamole]] myocardial perfusion imaging in patients with severe [[coronary calcification]] on [[EBCT]] but with one of the following baseline [[ECG]] abnormalities:
'''3.'''[[Adenosine]] or [[dipyridamole]] myocardial perfusion imaging in patients with severe [[coronary calcification]] on [[EBCT]] but with one of the following baseline [[ECG]] abnormalities:
:a. Electronically paced ventricular rhythm ''(Level of Evidence: C)''
:a. Electronically paced ventricular rhythm ''(Level of Evidence: C)''
:b. [[Left bundle-branch block]]. ''(Level of Evidence: C)''
:b. [[Left bundle-branch block]]. ''(Level of Evidence: C)''


4. [[Adenosine]] or [[dipyridamole]] myocardial perfusion imaging or [[dobutamine]] [[echocardiography]] in patients with possible [[myocardial ischemia]] on [[AECG]] monitoring or with [[coronary calcification]] on [[EBCT]] who are unable to exercise. ''(Level of Evidence: C)''
'''4.'''[[Adenosine]] or [[dipyridamole]] myocardial perfusion imaging or [[dobutamine]] [[echocardiography]] in patients with possible [[myocardial ischemia]] on [[AECG]] monitoring or with [[coronary calcification]] on [[EBCT]] who are unable to exercise. ''(Level of Evidence: C)''


5. Exercise [[myocardial perfusion]] imaging or exercise [[echocardiography]] after exercise [[ECG]] testing in asymptomatic patients with an intermediate-risk or high-risk Duke treadmill score. ''(Level of Evidence: C)''
'''5.''' Exercise [[myocardial perfusion]] imaging or exercise [[echocardiography]] after exercise [[ECG]] testing in asymptomatic patients with an intermediate-risk or high-risk Duke treadmill score. ''(Level of Evidence: C)''


6. [[Adenosine]] or [[dipyridamole]] myocardial perfusion imaging or [[dobutamine]] [[echocardiography]] after exercise [[ECG]] testing in asymptomatic patients with an inadequate exercise [[ECG]]. ''(Level of Evidence: C)''
'''6.'''[[Adenosine]] or [[dipyridamole]] myocardial perfusion imaging or [[dobutamine]] [[echocardiography]] after exercise [[ECG]] testing in asymptomatic patients with an inadequate exercise [[ECG]]. ''(Level of Evidence: C)''


===Class III===
===Class III===
1. Exercise [[ECG]] testing without an imaging modality in asymptomatic patients with possible [[myocardial ischemia]] on [[AECG]] monitoring or with [[coronary calcification]] on [[EBCT]] but with the baseline [[ECG]] abnormalities listed under Class IIb1 above. ''(Level of Evidence: B)''
'''1.''' Exercise [[ECG]] testing without an imaging modality in asymptomatic patients with possible [[myocardial ischemia]] on [[AECG]] monitoring or with [[coronary calcification]] on [[EBCT]] but with the baseline [[ECG]] abnormalities listed under Class IIb1 above. ''(Level of Evidence: B)''


2. Exercise [[ECG]] testing without an imaging modality in asymptomatic patients with an established diagnosis of [[CAD]] owing to prior [[MI]] or [[coronary angiography]]; however, testing can assess functional capacity and prognosis. ''(Level of Evidence: B)''
'''2.''' Exercise [[ECG]] testing without an imaging modality in asymptomatic patients with an established diagnosis of [[CAD]] owing to prior [[MI]] or [[coronary angiography]]; however, testing can assess functional capacity and prognosis. ''(Level of Evidence: B)''


3. Exercise or [[dobutamine]] [[echocardiography]] in asymptomatic patients with [[left bundle-branch block]]. ''(Level of Evidence: C)''
'''3.''' Exercise or [[dobutamine]] [[echocardiography]] in asymptomatic patients with [[left bundle-branch block]]. ''(Level of Evidence: C)''


4. [[Adenosine]] or [[dipyridamole]] myocardial perfusion imaging or [[dobutamine]] [[echocardiography]] in asymptomatic patients who are able to exercise and who do not have [[left bundle-branch block]] or electronically paced ventricular rhythm. ''(Level of Evidence: C)''
'''4.'''[[Adenosine]] or [[dipyridamole]] myocardial perfusion imaging or [[dobutamine]] [[echocardiography]] in asymptomatic patients who are able to exercise and who do not have [[left bundle-branch block]] or electronically paced ventricular rhythm. ''(Level of Evidence: C)''


5. Exercise myocardial perfusion imaging, exercise [[echocardiography]], [[adenosine]] or [[dipyridamole]] myocardial perfusion imaging, or [[dobutamine]] [[echocardiography]] after exercise [[ECG]] testing in asymptomatic patients with a low-risk Duke treadmill score. ''(Level of Evidence: C)''}}
'''5.''' Exercise myocardial perfusion imaging, exercise [[echocardiography]], [[adenosine]] or [[dipyridamole]] myocardial perfusion imaging, or [[dobutamine]] [[echocardiography]] after exercise [[ECG]] testing in asymptomatic patients with a low-risk Duke treadmill score. ''(Level of Evidence: C)''}}


==ACC / AHA Guidelines- Coronary Angiography for Risk Stratification in Asymptomatic Patients (DO NOT EDIT)<ref name="Gibbons2">Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, Ferguson TB Jr, Fihn SD, Fraker TD Jr, Gardin JM, O'Rourke RA, Pasternak RC, Williams SV, Gibbons RJ, Alpert JS, Antman EM, Hiratzka LF, Fuster V, Faxon DP, Gregoratos G, Jacobs AK, Smith SC Jr; American College of Cardiology; American Heart Association Task Force on Practice Guidelines. Committee on the Management of Patients With Chronic Stable Angina. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation. 2003 Jan 7; 107 (1): 149-58. PMID 12515758 </ref>==
==ACC / AHA Guidelines- Coronary Angiography for Risk Stratification in Asymptomatic Patients (DO NOT EDIT)<ref name="Gibbons2">Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, Ferguson TB Jr, Fihn SD, Fraker TD Jr, Gardin JM, O'Rourke RA, Pasternak RC, Williams SV, Gibbons RJ, Alpert JS, Antman EM, Hiratzka LF, Fuster V, Faxon DP, Gregoratos G, Jacobs AK, Smith SC Jr; American College of Cardiology; American Heart Association Task Force on Practice Guidelines. Committee on the Management of Patients With Chronic Stable Angina. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation. 2003 Jan 7; 107 (1): 149-58. PMID 12515758 </ref>==
{{cquote|
{{cquote|
===Class IIa===
===Class IIa===
1. Patients with high-risk criteria that suggest [[ischemia]] on noninvasive testing. ''(Level of Evidence: C)''
'''1.''' Patients with high-risk criteria that suggest [[ischemia]] on noninvasive testing. ''(Level of Evidence: C)''


===Class IIb===
===Class IIb===
1. Patients with inadequate prognostic information after noninvasive testing. ''(Level of Evidence: C)''
'''1.''' Patients with inadequate prognostic information after noninvasive testing. ''(Level of Evidence: C)''


===Class III===
===Class III===
1. Patients who prefer to avoid [[revascularization]]. ''(Level of Evidence: C)''}}
'''1.''' Patients who prefer to avoid [[revascularization]]. ''(Level of Evidence: C)''}}


==See Also==
==See Also==
Line 192: Line 184:
{{Reflist|2}}
{{Reflist|2}}


 
[[Category: Disease state]]
[[{{PAGENAME}}#Overview|''Return to top'']]
[[Category: Ischemic heart diseases]]
 
[[Category: Cardiology]]
 
[[Category: Emergency medicine]]
{{Circulatory system pathology}}
{{SIB}}
 
[[Category:Cardiology]]


{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}

Revision as of 22:21, 17 July 2011

Chronic stable angina Microchapters

Acute Coronary Syndrome Main Page

Home

Patient Information

Overview

Historical Perspective

Classification

Classic
Chronic Stable Angina
Atypical
Walk through Angina
Mixed Angina
Nocturnal Angina
Postprandial Angina
Cardiac Syndrome X
Vasospastic Angina

Differentiating Chronic Stable Angina from Acute Coronary Syndromes

Pathophysiology

Epidemiology and Demographics

Risk Stratification

Pretest Probability of CAD in a Patient with Angina

Prognosis

Diagnosis

History and Symptoms

Physical Examination

Test Selection Guideline for the Individual Basis

Laboratory Findings

Electrocardiogram

Exercise ECG

Chest X Ray

Myocardial Perfusion Scintigraphy with Pharmacologic Stress

Myocardial Perfusion Scintigraphy with Thallium

Echocardiography

Exercise Echocardiography

Computed coronary tomography angiography(CCTA)

Positron Emission Tomography

Ambulatory ST Segment Monitoring

Electron Beam Tomography

Cardiac Magnetic Resonance Imaging

Coronary Angiography

Treatment

Medical Therapy

Revascularization

PCI
CABG
Hybrid Coronary Revascularization

Alternative Therapies for Refractory Angina

Transmyocardial Revascularization (TMR)
Spinal Cord Stimulation (SCS)
Enhanced External Counter Pulsation (EECP)
ACC/AHA Guidelines for Alternative Therapies in patients with Refractory Angina

Discharge Care

Patient Follow-Up
Rehabilitation

Secondary Prevention

Guidelines for Asymptomatic Patients

Noninvasive Testing in Asymptomatic Patients
Risk Stratification by Coronary Angiography
Pharmacotherapy to Prevent MI and Death in Asymptomatic Patients

Landmark Trials

Case Studies

Case #1

Chronic stable angina risk stratification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Chronic stable angina risk stratification

CDC onChronic stable angina risk stratification

Chronic stable angina risk stratification in the news

Blogs on Chronic stable angina risk stratification

to Hospitals Treating Chronic stable angina risk stratification

Risk calculators and risk factors for Chronic stable angina risk stratification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-in-Chief: Cafer Zorkun, M.D., Ph.D. [2]; Smita Kohli, M.D.

Overview

The average mortality in patients with stable angina ranges from 1-3%.However, there is a wide variability in the prognosis and hence it is important to risk stratify every patient. Risk stratification is based on 4 types of patient characteristics.

  • Left ventricular function, which is the strongest predictor of long term survival
  • Extent of atherosclerosis in the coronary arteries
  • Evidence of a recent coronary plaque rupture
  • Overall health and presence of other co-morbidities.

An initial scoring system was proposed by the Framingham Heart Study group to predict 10 year risk for CAD based on patient's age, sex, total cholesterol, presence of hypertension and history of smoking and diabetes. Presence of other peripheral vascular diseases is also used to risk stratify the patients.

Risk Stratification of Chronic Stable Angina

ECG/Chest X-ray in asymptomatic patients

Presence of ECG abnormalities at rest puts the patient at higher risk than those with normal resting ECG. ECG abnormalities may be present in the form of LVH by ECG criteria, persistent ST-T wave inversions in V1-V3, Q waves in multiple leads or R wave in V1, bundle branch blocks and atrial or ventricular arrythmias. Presence of cardiomegaly or pulmonary vascular congestion on Ches X-ray are also associated with poor prognosis.

Importance of assessing Left Ventricular function

Indications for assessing LV function are not only limited to patients with evidence of heart failure or valvular dysfunction but also includes patients with documented MI or ECG showing Q waves(suggestive of old MI). A resting or exercise LV ejection fraction of less than 35% is associated with significant higher mortality than a normal EF. Echocardiography is the best initial tool for obtaining an estimate of the LV function, both systolic and diastolic. In addition to this, it will also provide information about associated valvular dysfunction and pulmonary artery pressures. This information can in turn be used to select or modify the treatment regimen for the patient.

ACC / AHA Guidelines- Measurement of rest LV function by echocardiography or radionuclide angiography (DO NOT EDIT)[1]

“

Class I

1. Echocardiography or radionuclide angiography (RNA) in patients with a history of prior MI, pathological Q waves, or symptoms or signs suggestive of heart failure to assess LV function. (Level of Evidence: B)

2.Echocardiography in patients with a systolic murmur suggesting mitral regurgitation to assess its severity and etiology. (Level of Evidence: C)

3.Echocardiography or RNA in patients with complex ventricular arrhythmias to assess LV function. (Level of Evidence: B)

Class III

1. Routine periodic reassessment of stable patients for whom no new change in therapy is contemplated. (Level of Evidence: C)

2. Patients with a normal ECG, no history of MI, and no symptoms or signs suggestive of heart failure. (Level of Evidence: B)

”


Exercise testing for Risk Stratification and Prognosis

ACC / AHA Guidelines- Risk Assessment and Prognosis in Patients With an Intermediate or High Probability of CAD (DO NOT EDIT)[1]

“

Class I

1. Patients undergoing initial evaluation. (Exceptions are listed below in classes IIb and III.) (Level of Evidence: B)

2. Patients after a significant change in cardiac symptoms. (Level of Evidence: C)

Class IIb

1. Patients with the following ECG abnormalities:

a. Preexcitation (Wolff-Parkinson-White) syndrome. (Level of Evidence: B)
b. Electronically paced ventricular rhythm. (Level of Evidence: B)
c. More than 1 mm of rest ST depression. (Level of Evidence: B)
d. Complete left bundle-branch block. (Level of Evidence: B)

2. Patients who have undergone cardiac catheterization to identify ischemia in the distribution of a coronary lesion of borderline severity. (Level of Evidence: C)

3.Postrevascularization patients who have a significant change in anginal pattern suggesting ischemia. (Level of Evidence: C)

Class III

1. Patients with severe comorbidity likely to limit life expectancy or prevent revascularization. (Level of Evidence: C)

”

ACC / AHA Guidelines- Cardiac Stress Imaging for Risk Stratification of Patients With Chronic Stable Angina Who Are Able to Exercise (DO NOT EDIT)[1]

“

Class I

1. Exercise myocardial perfusion imaging or exercise echocardiography to identify the extent, severity, and location of ischemia in patients who do not have left bundle-branch block or an electronically paced ventricular rhythm and have either an abnormal rest ECG or are using digoxin. (Level of Evidence: B)

2.Dipyridamole or adenosine myocardial perfusion imaging in patients with left bundle-branch block or electronically paced ventricular rhythm. (Level of Evidence: B)

3. Exercise myocardial perfusion imaging or exercise echocardiography to assess the functional significance of coronary lesions (if not already known) in planning PTCA. (Level of Evidence: B)

Class IIb

1. Exercise or dobutamine echocardiography in patients with left bundle-branch block. (Level of Evidence: C)

2. Exercise, dipyridamole, adenosine myocardial perfusion imaging, or exercise or dobutamine echocardiography as the initial test in patients who have a normal rest ECG and are not taking digoxin. (Level of Evidence: B)

Class III

1. Exercise myocardial perfusion imaging in patients with left bundle-branch block. (Level of Evidence: C)

2. Exercise, dipyridamole, adenosine myocardial perfusion imaging, or exercise or dobutamine echocardiography in patients with severe comorbidity likely to limit life expectation or prevent revascularization. (Level of Evidence: C)

”


ACC / AHA Guidelines- Cardiac Stress Imaging as the Initial Test for Risk Stratification of Patients With Chronic Stable Angina Who Are Unable to Exercise (DO NOT EDIT)[1]

“

Class I

1.Dipyridamole or adenosine myocardial perfusion imaging or dobutamine echocardiography to identify the extent, severity, and location of ischemia in patients who do not have left bundle-branch block or electronically paced ventricular rhythm. (Level of Evidence: B)

2.Dipyridamole or adenosine myocardial perfusion imaging in patients with left bundle-branch block or electronically paced ventricular rhythm. (Level of Evidence: B)

3.Dipyridamole or adenosine myocardial perfusion imaging or dobutamine echocardiography to assess the functional significance of coronary lesions (if not already known) in planning PTCA. (Level of Evidence: B)

Class IIb

1.Dobutamine echocardiography in patients with left bundle-branch block. (Level of Evidence: C)

Class III

1.Dipyridamole or adenosine myocardial perfusion imaging or dobutamine echocardiography in patients with severe comorbidity likely to limit life expectation or prevent revascularization. (Level of Evidence: C)

”

ACC / AHA Guidelines- Coronary Angiography and Left Ventriculography (DO NOT EDIT)[1]

“

Class I

1. Patients with disabling (Canadian Cardiovascular Society (CCS) classes III and IV) chronic stable angina despite medical therapy. (Level of Evidence: B)

2. Patients with high-risk criteria on noninvasive testing regardless of anginal severity. (Level of Evidence: B)

3. Patients with angina who have survived sudden cardiac death or serious ventricular arrhythmia. (Level of Evidence: B)

4. Patients with angina and symptoms and signs of congestive heart failure. (Level of Evidence: C)

5. Patients with clinical characteristics that indicate a high likelihood of severe CAD. (Level of Evidence: C)

Class IIa

1. Patients with significant LV dysfunction (ejection fraction <45%), CCS class I or II angina, and demonstrable ischemia but less than high-risk criteria on noninvasive testing. (Level of Evidence: C)

2. Patients with inadequate prognostic information after noninvasive testing. (Level of Evidence: C)

Class IIb

1. Patients with CCS class I or II angina, preserved LV function (ejection fraction >45%), and less than high-risk criteria on noninvasive testing. (Level of Evidence: C)

Class III

1. Patients with CCS class I or II angina who respond to medical therapy and have no evidence of ischemia on noninvasive testing. (Level of Evidence: C)

2. Patients who prefer to avoid revascularization. (Level of Evidence: C)

”

Asymptomatic patients

ACC / AHA Guidelines- Noninvasive Testing for the Diagnosis of Obstructive CAD and Risk Stratification in Asymptomatic Patients (DO NOT EDIT)[2]

“

Class IIb

1. Exercise ECG testing without an imaging modality in asymptomatic patients with possible myocardial ischemia on ambulatory ECG (AECG) monitoring or with severe coronary calcification on EBCT in the absence of one of the following ECG abnormalities:

a. Preexcitation (Wolff-Parkinson-White) syndrome (Level of Evidence: C)
b. Electronically paced ventricular rhythm (Level of Evidence: C)
c. More than 1 mm of ST depression at rest (Level of Evidence: C)
d. Complete left bundle-branch block. (Level of Evidence: C)

2. Exercise perfusion imaging or exercise echocardiography in asymptomatic patients with possible myocardial ischemia on AECG monitoring or with severe coronary calcification on EBCT who are able to exercise and have one of the following baseline ECG abnormalities:

a. Preexcitation (Wolff-Parkinson-White) syndrome (Level of Evidence: C)
b. More than 1 mm of ST depression at rest. (Level of Evidence: C)

3.Adenosine or dipyridamole myocardial perfusion imaging in patients with severe coronary calcification on EBCT but with one of the following baseline ECG abnormalities:

a. Electronically paced ventricular rhythm (Level of Evidence: C)
b. Left bundle-branch block. (Level of Evidence: C)

4.Adenosine or dipyridamole myocardial perfusion imaging or dobutamine echocardiography in patients with possible myocardial ischemia on AECG monitoring or with coronary calcification on EBCT who are unable to exercise. (Level of Evidence: C)

5. Exercise myocardial perfusion imaging or exercise echocardiography after exercise ECG testing in asymptomatic patients with an intermediate-risk or high-risk Duke treadmill score. (Level of Evidence: C)

6.Adenosine or dipyridamole myocardial perfusion imaging or dobutamine echocardiography after exercise ECG testing in asymptomatic patients with an inadequate exercise ECG. (Level of Evidence: C)

Class III

1. Exercise ECG testing without an imaging modality in asymptomatic patients with possible myocardial ischemia on AECG monitoring or with coronary calcification on EBCT but with the baseline ECG abnormalities listed under Class IIb1 above. (Level of Evidence: B)

2. Exercise ECG testing without an imaging modality in asymptomatic patients with an established diagnosis of CAD owing to prior MI or coronary angiography; however, testing can assess functional capacity and prognosis. (Level of Evidence: B)

3. Exercise or dobutamine echocardiography in asymptomatic patients with left bundle-branch block. (Level of Evidence: C)

4.Adenosine or dipyridamole myocardial perfusion imaging or dobutamine echocardiography in asymptomatic patients who are able to exercise and who do not have left bundle-branch block or electronically paced ventricular rhythm. (Level of Evidence: C)

5. Exercise myocardial perfusion imaging, exercise echocardiography, adenosine or dipyridamole myocardial perfusion imaging, or dobutamine echocardiography after exercise ECG testing in asymptomatic patients with a low-risk Duke treadmill score. (Level of Evidence: C)

”

ACC / AHA Guidelines- Coronary Angiography for Risk Stratification in Asymptomatic Patients (DO NOT EDIT)[2]

“

Class IIa

1. Patients with high-risk criteria that suggest ischemia on noninvasive testing. (Level of Evidence: C)

Class IIb

1. Patients with inadequate prognostic information after noninvasive testing. (Level of Evidence: C)

Class III

1. Patients who prefer to avoid revascularization. (Level of Evidence: C)

”

See Also

Sources

  • The ACC/AHA/ACP–ASIM Guidelines for the Management of Patients With Chronic Stable Angina [1]
  • TheACC/AHA 2002 Guideline Update for the Management of Patients With Chronic Stable Angina [2]
  • The 2007 Chronic Angina Focused Update of the ACC/AHA 2002 Guidelines for the Management of Patients With Chronic Stable Angina [3]

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP–ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). Circulation. 1999; 99: 2829–2848. PMID 10351980
  2. ↑ 2.0 2.1 2.2 Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, Ferguson TB Jr, Fihn SD, Fraker TD Jr, Gardin JM, O'Rourke RA, Pasternak RC, Williams SV, Gibbons RJ, Alpert JS, Antman EM, Hiratzka LF, Fuster V, Faxon DP, Gregoratos G, Jacobs AK, Smith SC Jr; American College of Cardiology; American Heart Association Task Force on Practice Guidelines. Committee on the Management of Patients With Chronic Stable Angina. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation. 2003 Jan 7; 107 (1): 149-58. PMID 12515758
  3. ↑ Fraker TD Jr, Fihn SD, Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, Ferguson TB Jr, Gardin JM, O'Rourke RA, Williams SV, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW; American College of Cardiology; American Heart Association; American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group. 2007 chronic angina focused update of the ACC/AHA 2002 Guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines for the management of patients with chronic stable angina. Circulation. 2007 Dec 4; 116 (23): 2762-72. Epub 2007 Nov 12. PMID 17998462


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Chronic_stable_angina_risk_stratification&oldid=577468"